Viridian Therapeutics (NASDAQ:VRDN) Sees Strong Trading Volume – Here’s What Happened

Viridian Therapeutics, Inc. (NASDAQ:VRDN) shares saw unusually-strong trading volume on Monday . Approximately 2,196,079 shares were traded during trading, an increase of 27% from the previous session’s volume of 1,725,198 shares.The stock last traded at $15.28 and had previously closed at $18.84.

More Viridian Therapeutics News

Here are the key news stories impacting Viridian Therapeutics this week:

• Positive Sentiment: Goldman Sachs cut its price target from $36 to $31 but kept a “buy” rating, implying substantial upside versus the current price and signaling continued analyst conviction. Benzinga
• Positive Sentiment: Royal Bank of Canada lowered its target from $42 to $30 but retained an “outperform” rating, again indicating analysts still see long‑term value despite near‑term headwinds. Benzinga
• Neutral Sentiment: Coverage roundup: a Globe & Mail piece groups Viridian with other healthcare names and summarizes recent analyst commentary — useful context but no new company‑specific catalyst. Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN) and Bristol-Myers Squibb (BMY)
• Negative Sentiment: Competitive clinical risk: Amgen reported positive Phase 3 results for a thyroid eye disease program (TEPEZZA OBI trial reported a 77% proptosis response), which investors view as direct competition to Viridian’s lead program and has been cited as a main reason for recent selling pressure. Why Is Viridian Therapeutics Stock Sinking Monday?
• Negative Sentiment: Press coverage highlights the Amgen link as the driver of the drop, increasing investor concern about VRDN’s addressable market and near‑term commercial prospects. Viridian Therapeutics Stock Is Tanking. Why the Drop Is Linked to This Amgen Study.
• Negative Sentiment: Sentiment/flow signal: unusual options activity — ~7,501 put contracts purchased (a large multiple of typical volume) — indicating hedging or speculative bearish bets that can accelerate downside moves in volatile sessions.
• Negative Sentiment: MSN and other outlets note VRDN has fallen to 9‑month lows amid the Amgen developments, underscoring the short‑term negative narrative investors are reacting to. VRDN stock falls to 9-month lows – what’s the Amgen connection?

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on VRDN shares. Wall Street Zen lowered shares of Viridian Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. Needham & Company LLC cut their price objective on shares of Viridian Therapeutics from $42.00 to $32.00 and set a “buy” rating for the company in a research report on Monday, March 30th. Royal Bank Of Canada cut their price objective on shares of Viridian Therapeutics from $42.00 to $30.00 and set an “outperform” rating for the company in a research report on Tuesday. Wedbush cut their price objective on shares of Viridian Therapeutics from $44.00 to $37.00 and set an “outperform” rating for the company in a research report on Tuesday, March 31st. Finally, The Goldman Sachs Group dropped their price target on shares of Viridian Therapeutics from $36.00 to $31.00 and set a “buy” rating for the company in a research report on Tuesday. Thirteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Viridian Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $38.00.

Viridian Therapeutics Price Performance

The company has a debt-to-equity ratio of 0.08, a current ratio of 12.65 and a quick ratio of 12.65. The stock has a market capitalization of $1.43 billion, a P/E ratio of -4.24 and a beta of 1.16. The company’s 50 day simple moving average is $27.58 and its two-hundred day simple moving average is $27.82.

Viridian Therapeutics (NASDAQ:VRDN) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($1.08) earnings per share for the quarter, missing the consensus estimate of ($0.90) by ($0.18). The firm had revenue of $0.13 million for the quarter, compared to the consensus estimate of $15.75 million. Viridian Therapeutics had a negative return on equity of 83.25% and a negative net margin of 483.57%. As a group, equities analysts expect that Viridian Therapeutics, Inc. will post -4.03 EPS for the current fiscal year.

Institutional Trading of Viridian Therapeutics

Several hedge funds have recently modified their holdings of the stock. Avoro Capital Advisors LLC bought a new stake in shares of Viridian Therapeutics during the fourth quarter valued at approximately $46,680,000. Seven Fleet Capital Management LP bought a new stake in shares of Viridian Therapeutics during the fourth quarter valued at approximately $456,000. Virtu Financial LLC bought a new stake in shares of Viridian Therapeutics during the fourth quarter valued at approximately $531,000. Invesco Ltd. grew its stake in shares of Viridian Therapeutics by 127.1% during the fourth quarter. Invesco Ltd. now owns 183,468 shares of the company’s stock valued at $5,710,000 after purchasing an additional 102,676 shares during the last quarter. Finally, XTX Topco Ltd bought a new position in Viridian Therapeutics in the fourth quarter valued at approximately $1,464,000.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.